MicroRNA-152 Acts As a Tumor Suppressor MicroRNA by Inhibiting Krüppel-Like Factor 5 in Human Cervical Cancer

Overview

Journal Oncol Res

Specialty Oncology

Date 2018 Aug 23

PMID 30131089

Citations 11

Authors

Haiyan Zhang

Yanxia Lu

Surong Wang

Xiugui Sheng

Shiqian Zhang

Affiliations

Soon will be listed here.

Abstract

Aberrant expression of microRNA-152 (miR-152) is frequently observed in human cancers including ovarian cancer, breast cancer, prostate cancer, and gastric cancer. However, its expression and functional role in cervical cancer (CC) are poorly understood. Also, the association between miR-152 and Krüppel-like factor 5 (KLF5) expression in CC remains unclear. In this study, analyzing the expression of miR-152 by quantitative real-time PCR (qRT-PCR) revealed it was sharply reduced in CC tissues and cell lines. In addition, the negative correlation of miR-152 expression and KLF5 expression was observed. The dual-luciferase reporter assay validated that KLF5 was a target of miR-152. In vitro functional assays revealed that miR-152 could inhibit cell proliferation and cell cycle progression through regulating the expression of KLF5. Taken together, our study suggested that miR-152 functions as a tumor suppressor in CC, and the miR-152/KLF5 axis may provide novel therapeutic targets for CC treatment.

Citing Articles

Autologous hGMSC-Derived iPS: A New Proposal for Tissue Regeneration.

Della Rocca Y, Diomede F, Konstantinidou F, Gatta V, Stuppia L, Benedetto U Int J Mol Sci. 2024; 25(17).

PMID: 39273117 PMC: 11395260. DOI: 10.3390/ijms25179169.

A time to heal: microRNA and circadian dynamics in cutaneous wound repair.

Fawcett S, Al Kassas R, Dykes I, Hughes A, Ghali F, Ross K Clin Sci (Lond). 2022; 136(8):579-597.

PMID: 35445708 PMC: 9069467. DOI: 10.1042/CS20220011.

Krüppel-like factor (KLF)5: An emerging foe of cardiovascular health.

Palioura D, Lazou A, Drosatos K J Mol Cell Cardiol. 2021; 163:56-66.

PMID: 34653523 PMC: 8816822. DOI: 10.1016/j.yjmcc.2021.10.002.

The role of HPV-induced epigenetic changes in cervical carcinogenesis (Review).

Da Silva M, Rodrigues de Albuquerque B, Allyrio T, Almeida V, Cobucci R, Bezerra F Biomed Rep. 2021; 15(1):60.

PMID: 34094536 PMC: 8165754. DOI: 10.3892/br.2021.1436.

Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.

Nunvar J, Pagacova L, Vojtechova Z, Trevisan Doimo de Azevedo N, Smahelova J, Salakova M Biomolecules. 2021; 11(5).

PMID: 34065237 PMC: 8160722. DOI: 10.3390/biom11050764.

References

Pasquinelli A . MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4):271-82. DOI: 10.1038/nrg3162. View

Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, Goodhill A . Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007; 370(9599):1609-21. DOI: 10.1016/S0140-6736(07)61684-5. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Xie D, Liang Y, Su Y, An Y, Qu P . miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression. Biomed Pharmacother. 2018; 99:299-305. DOI: 10.1016/j.biopha.2018.01.046. View

Wang X, Xu J, Cheng Z, Peng Q, Hu J, Gao L . [Study on effects of microRNA-21 antisense oligonucleotide in vivo and in vitro on bionomics of human cervical squamous carcinoma cell lines SiHa]. Zhonghua Bing Li Xue Za Zhi. 2012; 41(4):254-9. DOI: 10.3760/cma.j.issn.0529-5807.2012.04.009. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Pereira P, Marques J, Soares A, Carreto L, Santos M . MicroRNA expression variability in human cervical tissues. PLoS One. 2010; 5(7):e11780. PMC: 2909898. DOI: 10.1371/journal.pone.0011780. View

Liu L, Yu X, Guo X, Tian Z, Su M, Long Y . miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 2011; 5(3):753-60. DOI: 10.3892/mmr.2011.696. View

Wang Y, Wang D, Xie G, Yin Y, Zhao E, Tao K . MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. Oncotarget. 2017; 8(17):28125-28134. PMC: 5438636. DOI: 10.18632/oncotarget.15924. View

10.

Petry K . HPV and cervical cancer. Scand J Clin Lab Invest Suppl. 2014; 244:59-62. DOI: 10.3109/00365513.2014.936683. View

11.

Tang X, Lin L, Song L, Tang X . Hypoxia-inducible miR-152 suppresses the expression of WNT1 and ERBB3, and inhibits the proliferation of cervical cancer cells. Exp Biol Med (Maywood). 2015; 241(13):1429-37. PMC: 4994918. DOI: 10.1177/1535370215610442. View

12.

Zhu Q, Renaud H, Guo Y . Bioinformatics-based identification of miR-542-5p as a predictive biomarker in breast cancer therapy. Hereditas. 2018; 155:17. PMC: 5769523. DOI: 10.1186/s41065-018-0055-7. View

13.

Banno K, Yanokura M, Kisu I, Yamagami W, Susumu N, Aoki D . MicroRNAs in endometrial cancer. Int J Clin Oncol. 2013; 18(2):186-92. DOI: 10.1007/s10147-013-0526-9. View

14.

Gao D, Chen Y . Organoid development in cancer genome discovery. Curr Opin Genet Dev. 2015; 30:42-8. PMC: 4476933. DOI: 10.1016/j.gde.2015.02.007. View

15.

Schiffman M, Castle P, Jeronimo J, Rodriguez A, Wacholder S . Human papillomavirus and cervical cancer. Lancet. 2007; 370(9590):890-907. DOI: 10.1016/S0140-6736(07)61416-0. View

16.

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

17.

Gocze K, Gombos K, Juhasz K, Kovacs K, Kajtar B, Benczik M . Unique microRNA expression profiles in cervical cancer. Anticancer Res. 2013; 33(6):2561-7. View

18.

Borcoman E, Le Tourneau C . Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Ther Adv Med Oncol. 2017; 9(6):431-439. PMC: 5455883. DOI: 10.1177/1758834017708742. View

19.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

20.

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View